Riskpilot← Back to searchSign inGet full accessEbba Biotech AB
ABActiveOrg 5590167093Nobels Väg 16Research and experimental development on natural sciences and engineering · NACE 7210Est. 20154 employees
Revenue 2024
SEK 2,1M
+14% vs 2023
EBITDA margin
-94.9%
-16% vs 2023
Equity ratio
14.8%
Financial strength
Net profit 2024
SEK -2,1M
-16% vs 2023
| Revenue | SEK 2,1M | +14% |
| EBITDA | SEK -2M | -16% |
| Net profit | SEK -2,1M | -16% |
| Total assets | SEK 1,3M | +9% |
| Equity | SEK 197K | -30% |
| Employees | 4 | — |
Legal name
Ebba Biotech AB
Org number
5590167093
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
9 juni 2015
Share capital
SEK 62 500
Employees
4 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av Dahlfors, Lars Anders Christer Löffler, Susanne Katja
Company purpose
Bolagets verksamhet är att bedriva försäljning, utveckling och konsultverksamhet inom teknik-, hälso-, och sjukvårdsområdena samt jämte därmed förenlig verksamhet.
Address
Nobels Väg 16
Email
christer.dahlfors@ebbabiotech.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 243 | 352 | 556 | 1 162 | 1 487 | 1 851 | 2 113 |
| Staff expenses | — | — | — | — | — | — | — | — | −1 982 | −2 279 |
| EBITDA | −147 | −894 | −346 | −63 | −140 | −1 805 | −2 681 | −3 327 | −1 724 | −2 005 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −60 | −60 | −61 | −66 |
| EBIT | −147 | −894 | −346 | −63 | −140 | −1 805 | −2 741 | −3 387 | −1 785 | −2 070 |
| Net financials | — | — | 1 | — | — | −13 | −23 | −12 | −19 | −16 |
| Profit before tax | −147 | −894 | −348 | −63 | −140 | −1 818 | −2 764 | −3 399 | −1 804 | −2 086 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | — | — |
| Net profit | −147 | −894 | −348 | −63 | −140 | −1 818 | −2 764 | −3 399 | −1 804 | −2 086 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1 178 | 576 | 998 | 695 | 1 078 | 1 362 | 1 528 | 1 797 | 1 224 | 1 337 |
| Equity | 1 153 | 519 | 671 | 607 | 468 | 250 | 486 | 587 | 283 | 197 |
| Long-term debt | 0 | 0 | 0 | 0 | 200 | 400 | 800 | 400 | 500 | 775 |
| Short-term debt | 25 | 57 | 327 | 87 | 410 | 712 | 242 | 810 | 441 | 364 |
| Total debt | 25 | 57 | 327 | 87 | 610 | 1 112 | 1 042 | 1 210 | 941 | 1 139 |
EBITDA margin
-94.9%
This company
15.8%
Market median
-701% vs market
20152024
Equity ratio
14.8%
This company
38.2%
Market median
-61% vs market
20152024
Return on equity
-1056.4%
This company
18.4%
Market median
-5841% vs market
20152024
Net profit margin
-98.7%
This company
8.1%
Market median
-1319% vs market
20152024
Asset turnover
1.58×
This company
1.12×
Market median
+41% vs market
20152024
Debt / equity
5.77×
This company
0.62×
Market median
-831% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PÅ Chief Auditor | Chief Auditor | 2024 | — | — |
LR Chief Auditor | Chief Auditor | 2025 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2024 | — | — | |
| Board of Directors | 2021 | — | — | |
| Deputy Board Member | 2021 | — | — | |
| Chairman | 2021 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Deputy Board Member | 2021 | — | — | |
| Chairman | 2025 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Richter Life Science Development AB | Company | 80.0% | 80.0% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Richter Life Science Development AB
Ebba Biotech AB Board members of Ebba Biotech AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Åke Joakim Stomberg | Chief Auditor | 0 companies |
| Lars Rickard Jäderström | Chief Auditor | 0 companies |
| Lars Anders Christer Dahlfors | Deputy Board Member | 0 companies |
| Ulrica Magdalena Edlund | Board of Directors | 0 companies |
| Marie Madeleine Richter | Deputy Board Member | 0 companies |
| Astri Agneta Dahlfors | Chairman | 0 companies |
| Karin Sofie Nyström | Deputy Board Member | 0 companies |
| Xiankeng Choong | Deputy Board Member | 0 companies |
| Susanne Katja Löffler | Chairman | 0 companies |